Immunology Investor Event

DupixentⓇ - Strong driver of sustainable growth Sales in €bn €0.1bn 2017 DUPIXENT (dupilumab) Injection 200mg 300mg €0.8bn €2.1bn €3.5bn 2018 2019 2020 €5.2bn 2021 €13bn+ COPD not included¹ Accretive to BOI margin in 2022 Economies of scale driving profitability Manufacturing improvements continue Expansion into COPD 1. €13bn+ refers to the peak sales ambition, not including COPD. DupixentⓇ is under investigation in COPD and not yet approved by any regulatory agency to treat COPD. Immunology Investor Event 7 sanofi

View entire presentation